Impact of oral palonosetron in improving quality of life as compared to other oral 5-HT3 antagonists in delayed chemotherapy induced nausea and vomiting in patients of head and neck cancer

Anubhuti Khare; Varsha Mandloi; Abhishek Shrivastava; Arun Kumar Shrivastava; Prashant Wadagbalkar; Akhilesh Kumar

doi:10.18203/2319-2003.ijbcp20190653

Authors

Anubhuti Khare Department of Pharmacology, ABVGMC Vidisha, Madhya Pradesh, India http://orcid.org/0000-0001-5799-8295
Varsha Mandloi Department of Radiation Oncology, GMC, Bhopal, Madhya Pradesh, India
Abhishek Shrivastava Department of Radiation Oncology, ABVGMC, Vidisha, Madhya Pradesh, India
Arun Kumar Shrivastava Department of Pharmacology, GMC, Bhopal, Madhya Pradesh, India
Prashant Wadagbalkar Department of Pharmacology, ABVGMC Vidisha, Madhya Pradesh, India
Akhilesh Kumar Department of Pharmacology, ABVGMC Vidisha, Madhya Pradesh, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20190653

Keywords:

Delayed CINV, Complete response, Head and neck cancer, Quality of life

Abstract

Background: Chemotherapy induced nausea and vomiting (CINV) remains one of the most common and debilitating complications of highly emetogenic chemotherapy (HEC). This study was undertaken to evaluate palanosetron against other 5-HT3 receptor antagonists in preventing delayed CINV with the aim of achieving complete response (CR) and improving quality of life (QoL).

Methods: This was a prospective, observational study conducted on 75 histopathologically proven patients of squamous cell carcinoma of Head and Neck (H&N), who came to the Department of Radiation Oncology, Gandhi Medical College and Hamidia Hospital, Bhopal from January to December 2015. Standard protocol based chemotherapy containing highly emetogenic cisplatin based chemotherapy was administered to all the patients. For prevention of delayed chemotherapy induced nausea and vomiting all patients were prescribed oral 5-HT3 antagonists. Oral Ondansetron 4mg TDS was given to cohort 1, oral Granisetron 1 mg BD to cohort2 and oral Palanosetron 0.5mg OD was given to cohort 3. They were graded as complete response when they did not have complains of nausea and vomiting.

Results: In Ondansetron, Granisetron and in Palanosetron cohort 29%, 53% and 98% patients had complete response.

Conclusions: Palanosetron appears superior. Our study was conducted on handfull of patients and compared palanosetron against only two 5-HT3 receptor antagonists, so a larger study is suggested to establish the efficacy and better response of palanosetron.

Metrics

Metrics Loading ...

References

Kim KI, Lee DE, Cho I, Yoon JH, Yoon SS, Lee HS, et al. Effectiveness of Palonosetron Versus Other Serotonin 5-HT3 Receptor Antagonists in Triple Antiemetic Regimens During Multiday Highly Emetogenic Chemotherapy. Ann Pharmacotherap. 2012;46:1637-44.

Vicky TC, Yeo CW. Antiemetic therapy options for chemotherapy induced nausea and vomiting in breast cancer patients. Breast Cancer: Targets Therap. 2011;3:151–60.

Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, et al. Improved Prevention of Moderately Emetogenic Chemotherapy-Induced Nausea and Vomiting with Palonosetron, a Pharmacologically Novel 5-HT3 Receptor Antagonist, Results of a Phase III, Single-Dose Trial Versus Dolasetron. Cancer. 2003;98(11):2473-82.

Ruhlmann C, Herrstedt J. Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting, Expert Rev Anticancer Ther. 2010;10(2):137–48.

Liu L, Guo J, Fang S, Han X, Xie C, Liu J, et al. Therapeutic effects of palonosetron plus tropisetron on chemotherapy-induced nausea and vomiting. Int J Clin Exp Med. 2018;11(4):4108-13.

Aapro MS, Grunberg SM, Manikhas GM, Olivares G, Suarez T, Tjulandin SA, et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol. 2006;17(9):1441-9.

Jordan K, Hinke A, Grothey A. Ameta-analysis comparing the efficacy of four 5-HT3 receptor antagonists for acute chemotherapy induced emesis. Support Care Cancer. 2007;15:1023-33.

Billio A, Morello E, Clarke MJ. Serotonin receptor antagonists for highly emetogenic chemotherapy in adults. Cochrane Database Syst Rev. 2010;2010:CD006272.

Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003;14(10):1570-7.

Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol. 2009;10(2):115-24.

Celio L, Niger M, Ricchini F, Agustoni F. Palonosetron in the prevention of chemotherapy-induced nausea and vomiting: an evidence-based review of safety, efficacy, and place in therapy. Core Evid. 2015;10:75-87.

Gralla RJ, Navari RM, Hesketh PJ, Popovic W, Strupp J, Noy J, et al. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. J Clin Oncol. 1998;16:1568-73.